Advertisement

Basalganglienerkrankungen in der Intensivmedizin

  • W. H. Oertel
  • W. Fogel

Zusammenfassung

Basalganglienerkrankungen können auf zweierlei Arten intensivmedizinisch relevant werden: Zum einen können Komplikationen im Krankheitsverlauf selbst zu einer intensivmedizinischen Behandlungswürdigkeit führen, zum anderen können unwillkürliche Bewegungsstörungen den Verlauf anderer intensivmedizinisch behandlungsbedürftiger neurologischer oder internistischer Erkrankungen komplizieren.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arnold G, Trenkwalder C, Schwarz J, Oertel WH (1994) Zotepine reversibly induces akinesia and rigidity in PD patients with resting tremor or drug-induced psychosis. Mov Disord 9:238–240.CrossRefPubMedGoogle Scholar
  2. 2.
    Baratti M, Calzetti S (1984) Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 47:1241–1243.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cooper DR, Marrel C, Testa B et al. (1984) L-Dopa methyl ester — a candidate for chronic systemic delivery of L-Dopa in Parkinson’s disease. Clin Neuropharmacol 7:89–98.CrossRefPubMedGoogle Scholar
  4. 4.
    Durif F, Vidailhet M, Assai F, Roche C, Bonnet AM, Agid Y (1997) Low-dose clozapine improves dyskinesias in Parkinson’s disease. Neurology 48:658–662.CrossRefPubMedGoogle Scholar
  5. 5.
    Eichhorn TE, Brunt E, Oertel WH (1996) Ondansetron treatment of L-Dopa-induced psychosis. Neurology 47:1608–1609.CrossRefPubMedGoogle Scholar
  6. 6.
    Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 53:96–101.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39:1219–1221.CrossRefPubMedGoogle Scholar
  8. 8.
    Friedman JH, Feinberg SS, Feldman RG (1984) A neuroleptic malignant-like syndrome due to L-dopa withdrawal. Ann Neurol 16:126–127.Google Scholar
  9. 9.
    Gehlen W (1977) Akinetic crisis — a possible form of parkinsonism. Dtsch Med Wo-chenschr 102:255–256.Google Scholar
  10. 10.
    Goetz CG, Lütge W, Tanner CM (1986) Autonomic dysfunction in Parkinson’s disease. Neurology 36:73–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Kornhuber J, Weiler M, Riederer P (1993) Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm 6:63–72.CrossRefGoogle Scholar
  12. 12.
    Manyam BV (1997) Uncommon forms of tremor. In: Watts RL, Koller WC, (eds) Movement disorders. Neurologic principles and practice. McGraw-Hill, New York St. Louis, pp 387–403.Google Scholar
  13. 13.
    Nath A, Hobson DE, Russell A (1993) Movement Disorders with cerebral Toxoplasmo-sis and Aids. Mov Disord 8:107–112.CrossRefPubMedGoogle Scholar
  14. 14.
    Obeso JA, Artieda J, Quinn N et al. (1988) Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 11:529–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Oertel WH, Quinn NP (1996) Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (eds) Neurological disorders — Course and Treatment. Academic Press, San Diego, pp 715–772.Google Scholar
  16. 16.
    Ozelius LJ, Hewett JW, Page CE et al. (1997) The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 17:40–48.CrossRefPubMedGoogle Scholar
  17. 17.
    Poewe WH, Kleedorfer B, Wagner M et al. (1989) Side effects of subcutaneous apomor-phine in Parkinson’s disease. Lancet 1:1084–1085.CrossRefPubMedGoogle Scholar
  18. 18.
    Poewe WH, Oertel W (1994) Parkinson’s disease. In: Hacke W (ed) Neurocritical care. Springer, Berlin Heidelberg New York Tokio, pp 883–887.CrossRefGoogle Scholar
  19. 19.
    Rich SS, Friedman JH, Ott BR (1995) Risperidone vs. clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 56:556–559.PubMedGoogle Scholar
  20. 20.
    Rosin AJ, Devereux D, Eng N, Calne DB (1979) Parkinsonism with „on-off“ phenomena. Intravenous treatment with levodopa after major abdominal surgery. Arch Neurol 36:32–34.CrossRefPubMedGoogle Scholar
  21. 21.
    Sechi GP, Tanda F, Mutani R (1984) Fatal hyperpyrexia after withdrawal of levodopa. Neurology 34:249–251.CrossRefPubMedGoogle Scholar
  22. 22.
    Singer C, Berger JR, Bowen BC, Bruce JH, Weiner WJ (1993) Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoencephalopathy. Mov Disord 8:113–116.CrossRefPubMedGoogle Scholar
  23. 23.
    Tinker R, Anderson MG, Anand P, Kermode A, Harding AE (1990) Pontine myelinoly-sis presenting with acute parkinsonism as a sequel of corrected hyponatraemia [letter]. J Neurol Neurosurg Psychiatry 53:87–88.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wijdicks EF, Parisi JE, Sharbrough FW (1994) Prognostic value of myoclonus status in comatose survivors of cardiac arrest. Ann Neurol 35:239–243.CrossRefPubMedGoogle Scholar
  25. 25.
    Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology 47:1085–1087.CrossRefPubMedGoogle Scholar
  26. 26.
    Yamawaki Y, Ogawa N (1992) Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson’s disease. Intern Med 31:1298–1302.CrossRefPubMedGoogle Scholar
  27. 27.
    Zoldan J, Friedberg G, Livneh M, Melamed E (1995) Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45:1305–1308.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • W. H. Oertel
  • W. Fogel

There are no affiliations available

Personalised recommendations